×
About 340,302 results

ALLMedicine™ Hypertension Center

Research & Reviews  151,743 results

Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-as...
https://doi.org/10.1073/pnas.2010206118
Proceedings of the National Academy of Sciences of the Un... Gairhe S, Awad KS et. al.

Apr 10th, 2021 - Interferonopathies, interferon (IFN)-α/β therapy, and caveolin-1 (CAV1) loss-of-function have all been associated with pulmonary arterial hypertension (PAH). Here, CAV1-silenced primary human pulmonary artery endothelial cells (PAECs) were prolife...

Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hyper...
https://doi.org/10.1073/pnas.2023899118
Proceedings of the National Academy of Sciences of the Un... Masaki T, Okazawa M et. al.

Apr 10th, 2021 - Pulmonary arterial hypertension (PAH) is a devastating disease characterized by arteriopathy in the small to medium-sized distal pulmonary arteries, often accompanied by infiltration of inflammatory cells. Aryl hydrocarbon receptor (AHR), a nuclea...

Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and P...
https://doi.org/10.1177/10742484211006531
Journal of Cardiovascular Pharmacology and Therapeutics; Mandras S, Kovacs G et. al.

Apr 10th, 2021 - Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder characterized by vascular remodeling of the small pulmonary arteries, resulting in elevated pulmonary vascular resistance and ultimately, right ventricular failure. Expand...

see more →

Guidelines  567 results

Most COVID-19 hospitalizations due to four conditions
https://www.nih.gov/news-events/nih-research-matters/most-covid-19-hospitalizations-due-four-conditions
NIH Research Matters; National Institutes of Health (NIH)

Mar 8th, 2021 - Studies show that certain common medical conditions put people at higher risk for severe illness from COVID-19. These include metabolic disorders like type 2 diabetes and obesity, as well as heart conditions like high blood pressure (hypertension)...

Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for...
https://doi.org/10.1001/jama.2020.21749
JAMA , Krist AH et. al.

Nov 24th, 2020 - Cardiovascular disease (CVD) is a leading cause of death in the US. Known modifiable risk factors for CVD include smoking, overweight and obesity, diabetes, elevated blood pressure or hypertension, dyslipidemia, lack of physical activity, and unhe...

Screening for High Blood Pressure in Children and Adolescents: US Preventive Services T...
https://doi.org/10.1001/jama.2020.20122
JAMA , Krist AH et. al.

Nov 10th, 2020 - Prevalence of hypertension (both primary and secondary) in children and adolescents in the US ranges from 3% to 4%. Primary hypertension in children and adolescents occurs primarily in children older than 13 years and has no known cause but is ass...

Under Pressure: An Update on Pulmonary Hypertension
https://www.the-rheumatologist.org/article/under-pressure-an-update-on-pulmonary-hypertension/
The Rheumatologist; Liebowitz J.

Nov 8th, 2020 - In patients with connective tissue diseases, such as systemic sclerosis (SSc), pulmonary hypertension (PH) remains one of the leading causes of morbidity and mortality. In her lecture on Friday, Nov. 6, Pulmonary Hypertension: An Update, Mardi Gom...

Synopsis of the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense Cli...
https://doi.org/10.7326/M20-3798
Annals of Internal Medicine; Tschanz CMP, Cushman WC et. al.

Aug 31st, 2020 - In January 2020, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the diagnosis and management of hypertension in the primary care setting. The VA/DoD Evidence-B...

see more →

Drugs  9,169 results see all →

Clinicaltrials.gov  168,231 results

Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-as...
https://doi.org/10.1073/pnas.2010206118
Proceedings of the National Academy of Sciences of the Un... Gairhe S, Awad KS et. al.

Apr 10th, 2021 - Interferonopathies, interferon (IFN)-α/β therapy, and caveolin-1 (CAV1) loss-of-function have all been associated with pulmonary arterial hypertension (PAH). Here, CAV1-silenced primary human pulmonary artery endothelial cells (PAECs) were prolife...

Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hyper...
https://doi.org/10.1073/pnas.2023899118
Proceedings of the National Academy of Sciences of the Un... Masaki T, Okazawa M et. al.

Apr 10th, 2021 - Pulmonary arterial hypertension (PAH) is a devastating disease characterized by arteriopathy in the small to medium-sized distal pulmonary arteries, often accompanied by infiltration of inflammatory cells. Aryl hydrocarbon receptor (AHR), a nuclea...

Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and P...
https://doi.org/10.1177/10742484211006531
Journal of Cardiovascular Pharmacology and Therapeutics; Mandras S, Kovacs G et. al.

Apr 10th, 2021 - Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder characterized by vascular remodeling of the small pulmonary arteries, resulting in elevated pulmonary vascular resistance and ultimately, right ventricular failure. Expand...

see more →

News  10,429 results

Riociguat an Option for Pulmonary Arterial Hypertension When PDE-5 Inhibitors Fail
https://www.medscape.com/viewarticle/949018

Apr 8th, 2021 - NEW YORK (Reuters Health) - Patients with pulmonary arterial hypertension (PAH) at intermediate risk of death within a year may be switched from a phosphodiesterase-5 (PDE-5) inhibitor to riociguat to reduce risk, researchers suggest. "Decision ma...

When to Trust Those Home Blood Pressure Readings
https://www.medscape.com/viewarticle/948084

Apr 7th, 2021 - This transcript has been edited for clarity. Matthew F. Watto, MD: This is The Curbsiders. I'm Dr Matthew Watto, here with Dr Paul Williams. We are going to be talking about high blood pressure. We recently spoke with a fantastic expert: Dr Wanpen...

Post-COVID Wave Ahead of Death, Disability From Chronic Disease
https://www.medscape.com/viewarticle/948824

Apr 5th, 2021 - As a result of the COVID-19 pandemic, the United States will likely face a tsunami of death and disability from common chronic diseases that will affect society for decades, Robert Califf, MD, former commissioner of the US Food and Drug Administra...

Few Adults at Risk for Primary Aldosteronism Get Screened
https://www.medscape.com/viewarticle/948177

Mar 28th, 2021 - NEW YORK (Reuters Health) - Only 3% of adults at high risk for primary aldosteronism (PA) are screened for the condition, according to a study presented at ENDO 2021, the Endocrine Society's annual meeting. "Primary aldosteronism causes persistent...

Abuse of OTC Decongestant Potentially Deadly, FDA Warns
https://www.medscape.com/viewarticle/948125

Mar 24th, 2021 - Abuse or misuse of the over-the-counter (OTC) nasal decongestant propylhexedrine can cause serious harm that can lead to hospitalization, disability, or death, the US Food and Drug Administration (FDA) warns in a safety communication. "Major issue...

see more →

Patient Education  163 results see all →